Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:09960's Forward Dividend Yield % is ranked better than 96.72% of 61
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.88
vs HKSE:09960: 9.50
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Kindstar Globalgene Technology Forward Dividend Yield % Related Terms
HKSE:09960 vs TMO, DHR, NTRA: Forward Dividend Yield % Comparison
For the Diagnostics & Research subindustry, Kindstar Globalgene Technology's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kindstar Globalgene Technology Forward Dividend Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Kindstar Globalgene Technology's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Kindstar Globalgene Technology's Forward Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Kindstar Globalgene Technology Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
HKD 0.095000
2026-06-09
2026-06-11
2026-08-27
Cash Dividend
annually
HKD:HKD 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Dividend Yield % of 9.50% mean?
Kindstar Globalgene Technology (HKSE:09960) has a Forward Dividend Yield % of 9.50% as of Aug. 31, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Kindstar Globalgene Technology and its competitors. According to the industry distribution chart, Kindstar Globalgene Technology ranks #2 out of 61 companies in the Medical Diagnostics & Research industry, placing it in the top 3.3%.
Is Kindstar Globalgene Technology's Forward Dividend Yield % too high?
Kindstar Globalgene Technology's current Forward Dividend Yield % is 9.50%. The Medical Diagnostics & Research industry median Forward Dividend Yield % is 1.88. Kindstar Globalgene Technology's value of 9.50% is 405.3% above this industry median. Based on the distribution chart, Kindstar Globalgene Technology ranks #2 out of 61 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Kindstar Globalgene Technology has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kindstar Globalgene Technology's Forward Dividend Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Kindstar Globalgene Technology ranks #2 out of 61 companies for Forward Dividend Yield %. This places Kindstar Globalgene Technology in the top 3% of its industry — outperforming the majority of peers. The industry median Forward Dividend Yield % is 1.88. Kindstar Globalgene Technology's value of 9.50% is 405.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Medical Diagnostics & Research company?
The median Forward Dividend Yield % among Medical Diagnostics & Research companies is 1.88, based on 61 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kindstar Globalgene Technology's current Forward Dividend Yield % of 9.50% is 405.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Kindstar Globalgene Technology and its competitors. For the Medical Diagnostics & Research industry, the median Forward Dividend Yield % is 1.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kindstar Globalgene Technology's current Forward Dividend Yield % is 9.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kindstar Globalgene Technology stock overvalued right now?
Based on GuruFocus' analysis, Kindstar Globalgene Technology (HKSE:09960) is currently considered Fairly Valued. The stock's GF Value™ is HK$1.06, compared to a current price of HK$1.00 — trading 5.7% below its estimated fair value. The current Forward Dividend Yield % is 9.50% and 405.3% above the Medical Diagnostics & Research industry median of 1.88. Kindstar Globalgene Technology's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Kindstar Globalgene Technology (HKSE:09960), the current Forward Dividend Yield % is 9.50% as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kindstar Globalgene Technology (HKSE:09960) Overvalued in 2026?
Based on GuruFocus' analysis, Kindstar Globalgene Technology stock appears to be undervalued.
The current stock price of HK$1.00 is trading 5.7% below its estimated GF Value™ of HK$1.06.
GuruFocus considers Kindstar Globalgene Technology to be Fairly Valued.
Key valuation signals for HKSE:09960:
Forward Dividend Yield %: 9.50%
GF Value™: HK$1.06 vs. price of HK$1.00 (5.7% below fair value)
Industry Position: 405.3% above the Medical Diagnostics & Research median (#2 of 61)
No single metric tells the full story. See the HKSE:09960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kindstar Globalgene Technology Inc is engaged in the provision of clinical testing services in China. It operates in nine segments: Hematology testing segment includes testing services related to blood diseases; Genetic diseases and rare diseases segment includes testing services for rare diseases; Infectious diseases segment includes testing services from the infection department; Oncology segment includes testing related to oncology diseases; Neurology segment includes testing services related to neurological diseases undertaken by the Group; Maternity-related diseases segment includes testing services related to maternity; Routine testing segment conducts routine tests for the doctors daily diagnoses; CROs & R&D project segment includes research & develop services; & others segment.
69GF Score
Get the complete analysis for HKSE:09960
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09960 has been successfully added to your 
